Triple Negative Breast Cancer News and Research

RSS

RNA-binding proteins represent a new class of drug targets for triple-negative breast cancer

In cancer research, it's a common goal to find something about cancer cells -- some sort of molecule -- that drives their ability to survive, and determine if that molecule could be inhibited with a drug, halting tumor growth. Even better: The molecule isn't present in healthy cells, so they remain untouched by the new therapy.

2 Jul 2021

UTHSC researchers publish new findings on how obesity impacts cancer treatments

Liza Makowski, PhD, professor in the Department of Medicine and the UTHSC Center for Cancer Research, has long been interested in how the immune system is altered by obesity and how this impacts cancer risk and treatment.

25 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.

18 Jun 2021

Using natural killers from the immune system to target breast cancer cells

It sounds like a plot from a Quentin Tarantino movie -- something sets off natural killers and sends them on a killing spree.

16 Jun 2021

Study: Genetic mutations associated with breast cancer risk are the same in Black and white women

The prevalence of genetic mutations associated with breast cancer in Black and white women is the same, according to a new JAMA Oncology study of nearly 30,000 patients led by researchers in the Basser Center for BRCA at the Abramson Cancer Center. About five percent of both Black and white women have a genetic mutation that increases their risk of breast cancer.

14 Jun 2021

Major anti-cancer protein released by neutrophils selectively kills tumor cells

A study published in the June 10, 2021 issue of Cell describes a remarkable new mechanism by which the body's own immune system can eliminate cancer cells without damaging host cells.

10 Jun 2021

New technology predicts effectiveness of chemotherapy after one treatment

While early detection of breast cancer is critical, early prediction of how well the neoadjuvant chemotherapy treatment before surgery is working also may provide a window of opportunity when treatment could be altered and have a big impact on the patient's quality of life.

4 Jun 2021

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the world's largest clinical cancer research meeting.

1 Jun 2021

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.

19 May 2021

Incorrect DNA packaging makes retrotransposons more accessible

Scientists led by Dr. Salvador Aznar-Benitah, head of the Stem Cells and Cancer laboratory at IRB Barcelona, have described the alterations that occur during mammary gland formation when heterochromatin (the part of DNA that does not actively produce proteins) is poorly regulated.

18 May 2021

Researchers develop novel targeted therapy for triple-negative breast cancer

Researchers from Hong Kong Baptist University (HKBU), in collaboration with Cornell University, have developed a novel targeted therapy for triple-negative breast cancer (TNBC) that uses a specially-designed nano-carrier to deliver the Chinese medicine compound gambogic acid (GA).

12 May 2021

Triple Negative Breast Cancer News and Research

RNA-binding proteins represent a new class of drug targets for triple-negative breast cancer

UTHSC researchers publish new findings on how obesity impacts cancer treatments

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

Using natural killers from the immune system to target breast cancer cells

Study: Genetic mutations associated with breast cancer risk are the same in Black and white women

Major anti-cancer protein released by neutrophils selectively kills tumor cells

New technology predicts effectiveness of chemotherapy after one treatment

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

Incorrect DNA packaging makes retrotransposons more accessible

Researchers develop novel targeted therapy for triple-negative breast cancer

New class of anti-cancer compounds effectively kills liver and breast cancer cells

Low dose of a four-drug combination helps prevent cancer metastasis in mice

Penn State researchers develop a way to study microenvironment of breast cancer in 3D

Menopausal symptoms in breast cancer patients could be reduced through CBT delivered by nurses

Prolactin hormone acts as a major contributor to breast cancer development, studies find

Targeted therapy may be of great benefit in early stage breast cancer

CityU researchers identify super-enhancers that stimulate the activity of breast cancer genes

New research could rescue failed immunotherapies for treating solid tumors

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News